ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

January - March 2010, Volume 6, Issue 1
General Endocrinology


Piciu D, Irimie A, Duncea I, Popita V, Straciuc O, Pestean C, Piciu A, Bara A

Positron emission tomography - computer tomography fusion image, with 18-fluoro-2-deoxyD-glucose in the follow-up of patients with differentiated thyroid carcinoma

Acta Endo (Buc) 2010, 6 (1): 15-26
doi: 10.4183/aeb.2010.15

Aim. The aim of this study is to present the personal experience of the authors regarding the use of positron emission tomography-computer tomography fusion image (PET/CT), with 18Ffluoro-2-deoxy-D-glucose (FDG), in the follow-up of differentiated thyroid carcinoma (DTC).\r\nPatients and Methods. Twenty seven cases of DTC admitted and treated in the “Prof. Ion Chiricu??” Institute of Oncology Cluj-Napoca (IOCN), performed PET/CT investigation\r\nbetween 2007 and 2009, in DOTE Centre Debrecen (Hungary) and Pozitron Center Oradea (Romania). The patients underwent the surgical intervention and had histology of differentiated carcinoma; they received radioiodine therapy with I-131, had suppression therapy with thyroid hormones and had in the follow-up whole body scans (WBS) with I-131, neck ultrasound and serological determination of thyroglobulin (Tg) and anti-thyroglobulin antibodies (anti-Tg). All patients were referred to PET/CT after radical treatment, after a negative WBS I-131 and a dynamic increase of the serological level of Tg or anti-Tg, without any clinical signs of\r\nrecurrence and no neck ultrasound pathological findings.\r\nResults. All patients included in this study presented abnormal levels of Tg: between 2.76 ng/ml and 4173 ng/ml, with a median value of 43.15 ng/ml. In 23 cases (85.1%) the PET/CT results revealed the neoplasm recurrence, in 3 cases we obtained true negative results and in 1 case a false negative image; in 2 cases (7.4%) we found a second malignancy. All patients needed to change the treatment strategies.\r\nConclusion. The significant increase of the number of DTC and the more aggressive behaviour of the disease in some situations, determines the existence of a clear strategy of\r\ntreatment and monitoring, where the role of PET/CT is well defined.

Keywords: differentiated thyroid carcinoma, PET/CT 18F-FDG, follow-up

Correspondence: Doina Piciu MD, Institute of Oncology "Prof.Dr.Ion Chiricuta" - Nuclear Medicine Department, 34-36, Republicii St, Cluj-Napoca 400015, Romania, Tel: +4026-4450065,\r\nEmail: doina.piciu@gmail.com